Neurocrine's valbenazine misses in Phase IIb for Tourette syndrome

Neurocrine Biosciences Inc. (NASDAQ:NBIX) said valbenazine missed the primary endpoint in the Phase IIb T-Force GOLD trial to treat Tourette syndrome.

In 127 pediatric patients with moderate to severe Tourette syndrome, once-daily oral valbenazine failed to significantly improve motor and phonic tic symptoms as measured by Yale Global Tic Severity Scale (YGTSS) Total Tic Score from baseline to week 12 vs. placebo...